Fresenius Medical Care Posts Strong 2025 Results Amid Cautious 2026 Guidance

Shares of Fresenius Medical Care (FME) fell 7.1% despite the company reporting robust 2025 fiscal results, including 8% organic revenue growth across all operating segments. Operating income surged 27% to reach the top end of the company's guidance, with margins improving to 11.3% following successful cost-cutting initiatives. Earnings per share (EPS) saw a significant 44% increase, bolstered by an accelerated share buyback program, while the firm proposed a 3% dividend hike to EUR 1.49 per share. However, the stock faced heavy pressure as the fiscal year 2026 outlook forecasts operating income to remain flat due to substantial upcoming headwinds. This cautious guidance for the next year has overshadowed the strong 2025 performance, leading investors to re-evaluate the company's long-term growth trajectory and sustainability in the U.S. market.